Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 17/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 13/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 13/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 13/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 13/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 13/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20176151 | 0.87 | PSEN1 (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL20176167 | 0.80 | KDM4E (0.40) | — | |
| SCHEMBL17988491 | 0.74 | MAPK10 (0.30) | — | |
| SCHEMBL17661869 | 0.74 | NOTUM (0.53) | — | |
| SCHEMBL18328179 | 0.71 | TDO2 (0.41) | IDH1 | |
| SCHEMBL17661858 | 0.71 | IDH1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6124276 | 0.71 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18330398 | 0.70 | PSEN1 (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL17661845 | 0.70 | CYP3A4 (0.39) | — | |
| SCHEMBL16132838 | 0.70 | NOTUM (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180215755-A1 | FACTOR XIA MACROCYCLIC INHIBITORS BEARING ALKYL OR CYCLOALKYL P2' MOIETIES | BRISTOL MYERS SQUIBB CO (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180162821-A1 | FACTOR XIA MACROCYCLES WITH NOVEL P1 GROUPS | BRISTOL-MYERS SQUIBB COMPANY | 2018-06-14 | — | — | US | disclosed |
| US-20180141932-A1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141932-A1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | PSEN1 2609/4885PSEN2 2596/4885APH1B 1561/4885 |
| US-20180215755-A1 | FACTOR XIA MACROCYCLIC INHIBITORS BEARING ALKYL OR CYCLOALKYL P2' MOIETIES | TFPI, TFPI2, F11 | PSEN1 2031/4885PSEN2 1392/4885APH1B 1670/4885 |
| US-20180162821-A1 | FACTOR XIA MACROCYCLES WITH NOVEL P1 GROUPS | F11, F12, TFPI | PSEN1 217/4885PSEN2 637/4885APH1B 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.